GeneMatrix
Developing new diagnostic products for various diseases.
Launch date
Market cap
AUD75.9m
Enterprise valuation
AUD61m (Public information from Sep 2024)
Share price
KRW2880 109820.KQ
Seongnam-si Gyeonggi-do (HQ)
Financials
Estimates*
| KRW | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 15.9b | 12.1b | 11.2b | 9.8b |
| % growth | - | (24 %) | (7 %) | (12 %) |
| EBITDA | 2.4b | 186m | 471m | (1.5b) |
| % EBITDA margin | 15 % | 2 % | 4 % | (15 %) |
| Profit | 8.0b | (988m) | (8.1b) | (895m) |
| % profit margin | 50 % | (8 %) | (72 %) | (9 %) |
| R&D budget | 4.8b | 3.0b | 2.7b | 3.5b |
| R&D % of revenue | 30 % | 25 % | 24 % | 35 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$12.0m | Series A | ||
| N/A | N/A | IPO | |
| Total Funding | AUD18.5m | ||
Related Content
Recent News about GeneMatrix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
